Navigation Links
Gastroenterologists Applaud Kennedy-Hutchinson Bill's Renewal of War on Cancer
Date:3/26/2009

Strategies to Address Rare GI Cancers and Colorectal Screening Among Key Provisions

BETHESDA, Md., March 26 /PRNewswire-USNewswire/ -- The American College of Gastroenterology and its more than 10,000 physician members congratulate Senator Edward Kennedy and Senator Kay Bailey Hutchinson today for the introduction of "21st Century Cancer ALERT (Access to Life-Saving Early detection, Research and Treatment) Act" and their vow to renew the war on cancer. The bill would help focus the national scientific agenda on tackling deadly rare and ultra-rare cancers, including pancreas and esophagus cancers, while bringing much-needed resources to the major public health challenge of colorectal cancer, the second leading cause of cancer death in the United States although highly preventable through proven screening strategies.

"As the physicians on the front line of diagnosing life-threatening malignancies of the GI tract and digestive organs, we know first hand the devastation of cancers of the digestive system, particularly colorectal, esophageal and pancreatic cancers. We recognize Senator Kennedy and Senator Hutchinson for their leadership against these cancers, but particularly commend their targeted approach to increase use of preventive colorectal screening tests among low-income, uninsured Americans," said Eamonn Quigley, M.D., FACG, President of the American College of Gastroenterology.

Despite all the recent progress in raising public awareness of colorectal cancer prevention, significant barriers remain to utilization of screening tests, particularly for the uninsured. The Kennedy-Hutchinson cancer bill provides meaningful strategies to partner with states through the Centers for Disease Control and Prevention, with the aim of increasing use of colorectal cancer screening tests.

"This bill supports grants to states which screen patients for colorectal cancer by providing fin
'/>"/>

SOURCE American College of Gastroenterology
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. 7 outstanding young gastroenterologists receive AGA Foundation 2008 Research Scholars Award
2. Growing Shortage of Gastroenterologists to Affect Screening Capacity for #2 Cancer Killer
3. Surveyed Gastroenterologists Indicate That Humira Has Advantages Over Remicade in Maintaining Clinical Remission of Crohns Disease
4. AIDS Healthcare Foundation Applauds City Commissioners Support of Diversity, Urges Call for Mayors Resignation
5. Fairness Coalition Applauds Senate Passage of Mental Health Parity Bill
6. SNM applauds NAS study showing need to restore federal nuclear medicine research funding
7. Cardiac Science Applauds Mass AED Training of Pittsburgh Educators
8. Teamsters Applaud Passage of Legislation to Protect Workers From Diacetyl Exposure
9. Infectious diseases experts applaud bill against bad bugs
10. Coalition to Protect Floridas Drivers Applauds Governor Crist for Adding PIP to Special Session
11. AGD Applauds Congressional Support of SCHIP Reauthorization
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6COMFORCE Corporation to Hold Conference Call to Discuss Second Quarter 2009 Results 53484 1COMFORCE Corporation to Hold Conference Call to Discuss Second Quarter 2009 Results 53484 2Therapy Technique Cuts Divorce Separation Rate By Nearly 50 Percent 53482 1Therapy Technique Cuts Divorce Separation Rate By Nearly 50 Percent 53482 2Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 1Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 2Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 3Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 4